Impact of tDCS on Cannabis Craving in Patients With Schizophrenia and Cannabis Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
Impact of tDCS on Cannabis Craving in Patients With Schizophrenia and Cannabis Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
This study aims to evaluate the tDCS's impact on cannabis craving in patients with schizophrenia and cannabis addiction disorder.
The authors set up this randomized, double-blind multicenter study. 7 centers are participating in this research. After randomisation, the patient will have either the placebo or stimulation sessions, by tDCS, 5 session per day, for 5 days. The authors use the Marijuana Craving Questionnaire (MCQ) scale to determine the variation in cannabis craving and measure the impact of treatment on craving, as primary outcome.
secondary objectives include assessing the effect of tDCS on the general psychopathology of schizophrenia, cannabis and tobacco addiction, and on cognitive tests assessing attention and risk taking This study will be the first known multicenter study assessing tDCS impact on cannabis craving in schizophrenia.
Inclusion Criteria:
Patients (male or female) aged 18-65
Patients with schizophrenia according to DSM 5 criteria with Comorbid diagnosis of "cannabis use disorder"
Stabilized patients: total score = 80 at initial PANSS score and = 3 at the following PANSS points:
Patients without any other drug or psychotherapeutic treatment for cannabis dependence ("naive" patients)
Reported cannabis use greater than three times per week in the past three years
Signed consent to participate in research
Affiliation to a French social security scheme
Patient fluent in the French language
Exclusion Criteria:
urcve@gmail.com01 43 09 32 32
y.bencherif@epsve.fr01 43 09 32 32
bencherif.info@gmail.com0782723674